Why the study?
Aliskiren has cardioprotective and BP-lowering effects, but the effects of nanoparticle-loaded aliskiren on BP, NOS activity, and cardiovascular structural alterations in spontaneously hypertensive rats needed investigation.
Does nanoparticle-loaded aliskiren improve blood pressure and cardiovascular structural alterations in spontaneously hypertensive rats compared to powdered aliskiren?
Does nanoparticle-loaded aliskiren improve blood pressure and cardiovascular structural alterations in spontaneously hypertensive rats compared to powdered aliskiren?
Answers are grounded in this paper and cite their sources.
Nanoparticle-loaded aliskiren demonstrates enhanced antihypertensive and cardioprotective efficacy compared to standard powdered aliskiren in a hypertensive rat model.
Aliskiren, a renin inhibitor, has been shown to have cardioprotective and blood pressure (BP) lowering effects. We aimed to determine the effects of nanoparticle-loaded aliskiren on BP, nitric oxide synthase activity (NOS) and structural alterations of the heart and aorta developed due to spontaneous hypertension in rats. Twelve week-old male spontaneously hypertensive rats (SHR) were divided into the untreated group, group treated with powdered or nanoparticle-loaded aliskiren (25 mg/kg/day) and group treated with nanoparticles only for 3 weeks by gavage. BP was measured by tail-cuff plethysmography. NOS activity, eNOS and nNOS protein expressions, and collagen content were determined in both the heart and aorta. Vasoactivity of the mesenteric artery and wall thickness, inner diameter, and cross-sectional area (CSA) of the aorta were analyzed. After 3 weeks, BP was lower in both powdered and nanoparticle-loaded aliskiren groups with a more pronounced effect in the latter case. Only nanoparticle-loaded aliskiren increased the expression of nNOS along with increased NOS activity in the heart (by 30%). Moreover, nanoparticle-loaded aliskiren decreased vasoconstriction of the mesenteric artery and collagen content (by 11%), and CSA (by 25%) in the aorta compared to the powdered aliskiren group. In conclusion, nanoparticle-loaded aliskiren represents a promising drug with antihypertensive and cardioprotective effects.
No takes yet. Share an insight, caveat, or question.
Pecháňová et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: